WO2015073211A1 - Glucose rate increase detector: a meal detection module for the health monitoring system - Google Patents
Glucose rate increase detector: a meal detection module for the health monitoring system Download PDFInfo
- Publication number
- WO2015073211A1 WO2015073211A1 PCT/US2014/062991 US2014062991W WO2015073211A1 WO 2015073211 A1 WO2015073211 A1 WO 2015073211A1 US 2014062991 W US2014062991 W US 2014062991W WO 2015073211 A1 WO2015073211 A1 WO 2015073211A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meal
- glucose
- grid
- detection
- roc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/725—Details of waveform analysis using specific filters therefor, e.g. Kalman or adaptive filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
Definitions
- the primary goal of the artificial pancreas (AP) is to eliminate the occurrence of severe hypoglycemia and reduce the time spent in hyperglycemia (>180 mg/dL) in an effort to improve quality of life and reduce long-term complications.
- T1DM type 1 diabetes mellitus
- 1 Safe and effective control of type 1 diabetes mellitus (T1DM) using an AP has been researched widely for several decades, with many advances, but several challenges remain, including overcoming large meal disturbances, the effects of exercise, and the delays associated with subcutaneous glucose sensing and insulin delivery.
- T1DM type 1 diabetes mellitus
- One of the most challenging aspects of the diabetes therapy routine is dealing with meals, and it has been shown that inaccurate estimation of meal sizes occurs frequently, resulting in additional glucose fluctuations.
- 3 Recent behavioral studies have also shown that people with T1DM are interested in an automated system but are concerned with relinquishing full control. 4 ' 5 Therefore, an automatic AP that is safe and robust to daily living conditions and is trusted by the users is critical.
- the AP is a multi-layer device that will contain several features, including a core glucose controller, devices for monitoring of glucose and possibly other biologically relevant compounds or signals, software to interface with the user, safety systems to monitor the status of the system, and telemedicine to convey information about the system to the user and family and/or medical personnel.
- the core of the AP is the controller, the design of which has been explored by several research teams, with promising results 6"11 .
- Continuous glucose monitoring (COM) devices and insulin pumps are continually being improved, and are at a performance level that enables automatic control. 12 ' 13 Currently, longer clinical trials with several meals and exercise are being performed with good results.
- the Glucose Rate Increase Detector is a module of the Health Monitoring System (HMS) that has been designed as a component of the AP that operates in parallel to the controller.
- HMS Health Monitoring System
- the objective of the GRID is to detect persistent increases in glucose associated with a meal, and trigger a meal bolus to blunt the meal peak safely. It may be used in open- loop control, closed-loop control with user input, or fully automatic closed- loop control.
- Glucose management using continuous glucose monitoring and insulin pumps as well as the use of an artificial pancreas (AP) system that implements intensive insulin therapy has an inherent risk of adverse events such as hypoglycemia and hyperglycemia.
- Real-time prediction of pending adverse events by the Health Monitoring System (HMS) would allow prevention by either a corrective action or shifting to manual control.
- This invention is based on continuous glucose monitoring (CGM) data that provides a reliable layer of protection to insulin therapy, and provides a Glucose Rate Increase Detector (GRID) for the use with CGM Systems, Insulin pumps and the Artificial Pancreas (AP) for the detection of rises in glucose associated with meal events and for triggering of safe meal boluses.
- CGM continuous glucose monitoring
- GRID Glucose Rate Increase Detector
- the GRID is a module of the HMS that has been designed as a component of the AP that operates in parallel to the controller.
- the objective of the GRID is to detect persistent increases in glucose associated with a meal, and either trigger a meal bolus to blunt the meal peak safely (during closed-loop control) or alert the subject to bolus for a meal (open-loop control). It may be used in open- loop control, closed-loop control with user input, or fully automatic closed-loop control.
- the invention GRID provides a safety system that can accompany insulin pumps and continuous glucose monitoring systems, as well as artificial pancreas. The invention can be used to improve CGM capabilities in detecting meal disturbances and recommending correction boluses to provide better glycemic control, including less time in hyperglycemia.
- the invention provides a GRID for use in an artificial pancreas (AP), wherein the GRID detects in a person persistent increases in glucose associated with a meal, and either triggers a meal bolus to blunt meal peak safely, during closed-loop control, or alerts the person to bolus for a meal, during open- loop control.
- AP artificial pancreas
- the GRID comprises a GRID algorithm which uses CGM data to estimate the rate of change (ROC) of glucose and detect meal-related glucose excursions, the algorithm comprising: a) a pre-processing section to prepare the CGM data for analysis, b) an estimation section to approximate the ROC of glucose, and c) a detection section to logically pinpoint meal events.
- a pre-processing section to prepare the CGM data for analysis
- an estimation section to approximate the ROC of glucose
- a detection section to logically pinpoint meal events.
- the algorithm filters the CGM data using a noise-spike filter
- the ROC of glucose is calculated using the first derivative of a 3 -point Lagrangian interpolation polynomial, evaluated at the most recent point
- the detection section comprises a logic wherein the detection is positive and equal to 1 at the current point only if a corresponding filtered point is above a value (G m i n ) chosen large enough to isolate post-meal glucose values and to avoid the hypoglycemia region, and either the last three ROC values are above G m i n or the last two are above G m i n , wherein the ROC cutoffs are chosen to isolate post-meal rises, and provides a hierarchical approach, with either two at a higher ROC or three at a lower ROC, which allows faster detection with higher ROC values.
- the invention provides a GRID configured to provide the steps of Fig. 1.
- the invention provides a HMS for real-time prediction of pending adverse events based on CGM data, comprising a subject GRID and a controller, which provides prevention of the events by either a corrective action or shifting to manual control.
- the invention provides a method for providing a reliable layer of protection to insulin therapy, comprising detecting rises in glucose associated with meal events and triggering safe meal boluses, wherein the detecting and triggering steps are performed with a subject GRID with a CGM system, an insulin pump or an artificial pancreas (AP).
- the invention provides an artificial pancreas programmed and configured to implement the protocol of Fig. 2.
- the invention also provides corresponding algorithms for programming controllers
- the invention also provides a method comprising directing and optionally, delivering, insulin delivery using a subject GRID, controller, HMS or AP.
- Figure 1 Flow chart for GRID treatment protocols, followed after a meal is detected.
- Figure 2 Block diagram of a fully-automated AP with the GRID receiving CGM and insulin delivery information, and, upon detection of a meal, relaying a bolus recommendation to the Glucose Controller.
- Figure 3 Results for the GRID and Kalman Filter (KF), compared with the zone-MPC insulin response.
- Figure 4 Results of a cost-benefit analysis of sampling period on meal detection metrics using in silico data.
- Figure 5 Time in range results of an 18 h study of adult subjects using the UVA/Padova simulator with CHO meal at 4.5 h.
- Figure 6 Time in range results of a 24 h in silico study of 10 adult subjects using the UVA/Padova simulator with CHO meals.
- GRID Glucose Rate Increase Detector
- HMS Health Monitoring System
- the GRID algorithm was tuned on clinical data with 40 - 70 g CHO meals and tested on simulation data with 50 - 100 g CHO meals. Active closed and open-loop protocols were executed in silico with various treatments, including automatic boluses based on a 75 g CHO meal and boluses based on simulated user input of meal size. An optional function was used to reduce the recommended bolus using recent insulin and glucose history.
- the GRID improved median time in the 80-180 mg/dL range by 17% and in the >180 range by 14% over unannounced meals, using an automatic bolus for a 75 g CHO meal at detection.
- the GRID shifted the median glucose peak down by 73 mg/dL and earlier by 120 min and reduced the time >180 mg/dL by 57% over a missed- meal bolus scenario, using a full meal bolus at detection.
- the GRID improved closed-loop control in the presence of large meals, without increasing late postprandial hypoglycemia. Users of basal-bolus therapy could also benefit from GRID as a safety alert for missed meal corrections.
- the modules of the HMS are each designed to monitor a specific component of the AP, or type of adverse event or disturbance seamlessly without interference.
- the most prevalent and risky occurrence is hypoglycemia.
- the Low Glucose Predictor (LGP) was designed to predict and prevent severe hypoglycemia in parallel to a controller, and has been shown to be effective in clinic in combination with the zone-Model Predictive Control (zone-MPC) controller. 22"24
- GRID has been designed as the second module in the HMS, for the express purpose of detecting meal excursions with high specificity and short reaction time.
- the GRID algorithm uses CGM data to estimate the rate of change (ROC) of glucose and detect meal-related glucose excursions.
- the GRID consists of three main subsections: 1) a pre-processing section to prepare the CGM data for analysis, 2) an estimation section to approximate the ROC of glucose, and 3) a detection section to logically pinpoint meal events.
- the algorithm filters the data using a noise-spike filter:
- G FtNS (k) G F NS (k - l) - AG if (G f NS (k - l) - G m (k) ) > AG , (0)
- G F NS (k - 1) is the previous filtered value from the noise spike filter
- G FNS (k) is the filtered value resulting from the noise-spike filter
- G m (k) is the measurement
- AG is the maximum allowable ROC, set to 3 mg/dL in a one-minute period, to limit the ROC to a physiologically-probable value.
- T F is the filter time constant
- G F is the filtered value.
- the value for T F has been tuned to smooth the data without introducing a long delay to optimize the specificity and detection speed of the algorithm.
- the ROC of glucose is calculated using the first derivative of the 3 -point Lagrangian interpolation polynomial, evaluated at the most recent point, as r plausible 18,22
- the detection, GRID + is positive (equal to 1) at the current point only if the filtered point is above a value and ( ⁇ ) either the last three ROC values are above
- the value of is chosen large enough to isolate post-meal glucose values and to avoid the hypoglycemia region.
- the ROC cutoffs are chosen to isolate post-meal rises and the hierarchical approach (with either two at a higher ROC or three at a lower ROC) allows faster detection with higher ROC values.
- Kalman Filter Algorithm A standard Kalman Filter (KF) was used as a benchmark to evaluate the GRID
- the KF was a version of the Optimal Estimation algorithm used by Palerm, et al. , modified for use with 5 min sampling.
- the detection logic was implemented as it was in the GRID, and tuned along with the number of states (two states including glucose value and rate of change of glucose and three states including the acceleration of glucose as well) and the Q to R ratio for specificity and detection speed, resulting in slightly different tuning than the GRID.
- the RHC has two functions: 1) to calculate the insulin delivery over the last 60 min and subtract the amount over basal from the recommended bolus, and 2) to calculate a correction to 140 mg/dL for the lowest glucose value in the past 60 min and add it to the recommended bolus.
- the correction to 140 mg/dL can be negative, reducing the recommended bolus if recent glucose values were on the lower end of the target zone. This action provides an additional safeguard against over-delivery. All of these calculations are based on the clinical parameters of the subjects, including insulin to carbohydrate ratios and correction factors.
- HMS full incorporation of the HMS, including the GRID and the LGP is shown in Figures 1 and 2, with CGM information being sent to both LGP and GRID, and insulin information being sent to GRID to allow for calculation of the RHC.
- the HMS operates in parallel with the controller to minimize interference and also to reduce the likelihood of adverse safety events due to module failure.
- the GRID and KF algorithms were tuned using training data from clinical trials and tested on a validation set of clinical data and an in silico data set, all with unannounced meals. As mentioned above, the algorithms were tuned, in order of importance, for low detection time, low false positive rate (high specificity), and high number of meals positively identified. Study details from all trials are shown in
- the training data was comprised of 12 fully closed-loop, 24-h trials with subjects with T1DM using zone-MPC with a target zone of 80-140 mg/dL and HMS with LGP, performed at the Sansum Diabetes Research Institute using the Artificial Pancreas System (APS ® ). 33 The subjects were given small to medium-sized meals (40-50 g CHO) and performed 30 min of moderate exercise, with some subjects receiving 16 g CHO snacks before exercise, and several receiving 16 g rescue CHO per the HMS. All subjects used Dexcom ® SEVEN ® PLUS, (Dexcom ® San Diego, CA) CGMs with a 5 min sampling period, and received subcutaneous insulin delivery.
- the success of automatically rejecting the meal disturbance is highly dependent on the speed of detection. If detected too late, it may be of no use, or even cause hypoglycemia if too much insulin is delivered in excess of the controller correction.
- the simulator provides a sampling period of 1 min, so an analysis of the benefit of faster sampling rate on speed of detection, rise at detection, and the percentage of meals detected was performed.
- Standard Care Alert For subjects on standard basal-bolus therapy, meal boluses are sometimes missed,
- a missed meal bolus during standard basal-bolus therapy was simulated, to evaluate the ability of the algorithm to inform a CGM user of the missed bolus in a timely manner, blunting the glucose peak and decreasing the time in hyperglycemia.
- An 18 h scenario with a 50, 75, or 100 g CHO meal at 4.5 h was simulated with several protocols, shown in Table 2.
- User-input boluses are delivered at the cycle after detection to simulate the delay of waiting for user response.
- the GRID was integrated into the control scheme as a form of inferential control, by detecting the meal disturbance, calculating an insulin bolus to reject the disturbance, and feeding this information to the zone-MPC controller.
- the LGP module of the HMS was also active, with a prediction threshold of 65 mg/dL and an activation threshold of 100 mg/dL. 22 ' 23 ' 36 ' 37 A 24 h scenario with three meals of 50, 75, and 100 g CHO was performed, as above in the CHO per the HMS.
- T F 6 min
- 0 ⁇ 130 mg/dL
- C3 ⁇ 4 n 3 1.5 mg/dL/min
- C3 ⁇ 4 n 2 1.6 mg/dL/min.
- This combination of parameters resulted in a mean time to detection of 42 min from the start of the meal, 87.5% of meals detected within 2 h, and 1.6 false positive detections per day. Due to the large number of snacks and hypoglycemia rescues, adjusted values for meals detected and false positive alarms were calculated, resulting in 65% of all carbohydrate ingestions being detected and only 0.58 false positive detections per day.
- the mean time to detection was 45 min from the start of the meal, 79.2% of meals were detected within 2 h, and 1.5 false positive detections occurred per day.
- the adjusted calculation resulted in 57% of all carbohydrate ingestions being detected and only 0.58 false positive detections per day.
- Both algorithms were compared to the insulin response by the controller, quantified as the time from the start of the meal to the time when the average delivery over 15 min was more than 50% above the basal rate.
- the GRID yielded positive meal detections approximately 40-45 min from the start of meals, and reduced both the meal peaks and the duration of hyperglycemia, when compared to unannounced meals.
- the result of the delay in the bolus during GRID-active protocols is a large improvement over the missed meal protocol (B).
- the GRID module of the HMS was designed to accurately and quickly identify meal glucose excursions and logically recommend an insulin bolus to reject the meal disturbance.
- the algorithm was tuned using noisy clinical trial data with unannounced meals and several snacks, and the same controller used in the simulations. It should be noted that, while tuning for speed of detection was the first priority, any algorithms that produced more than 2.0 false positive detections per day were excluded. Even with those algorithms included, the fastest detection time would have been 35 min for KF or GRID. Thus, with controlled data and medium-sized meals, a 30+ min delay for meal detection based on CGM data is the limit of detection speed.
- the GRID is designed as a parallel module to the controller that focuses on meal detection, to trigger a rejection of the meal disturbance.
- This approach provides a more boluslike meal response by the controller, and the IOB constraint keeps over-delivery from occurring, essentially front-loading the insulin for the meal response without need for outside input.
- the disturbance rejection action was logically modified with by the RHC function, which reduced the recommended bolus by recent delivery and adjusted for recent glucose history.
- the GRID was able to improve control in the presence of large meals, without increasing the instances of hypoglycemia or increasing the time in the hypoglycemia range ( ⁇ 70 mg/dL), as seen in Figure 6 and Table 4.
- fast recognition of missed meal boluses in open-loop mode, for users on standard therapy can greatly improve the time in range and serve as a safety alert for users of the currently available devices.
- Figure 1 Flow chart for GRID treatment protocols, followed after a meal is detected. Automatic Mode protocols are in the box surrounded by a dashed line and User- Input Mode protocols are in the box surrounded by the dotted line.
- Figure 2 Block diagram of a fully-automated AP with the GRID receiving CGM and insulin delivery information, and, upon detection of a meal, relaying a bolus recommendation to the Glucose Controller.
- the HMS is outlined in a black solid line, with sub-modules GRID and LGP outlined in double lines, the controller in black solid and physical devices and the subject in dotted lines.
- Figure 3 Results for the GRID (no fill) and KF (45 degree lines), compared with the zone-MPC insulin response (45 degree cross hatches).
- A Training set from a 12-subject clinical trial using zone-MPC with two unannounced meals (50 and 40 g CHO);
- B Validation set from a 10-subject clinical trial using zone-MPC, with three unannounced meals (70, 40, and 70 g CHO); and
- C Simulation set from a 10-subject scenario, with three unannounced meals (50, 75, and 100 g CHO). (1) Time of detection; (2) rise in glucose at detection; (3) the percentage of meals that were detected within 2 h; (4) rate of false positive detections.
- Figure 4 Results of a cost-benefit analysis of sampling period on meal detection metrics using in silico data. Meals of 25, 50, 75, or lOOg CHO with no bolus are shown in diamonds, squares, circles, and triangles, respectively. Both Zone-MPC, shown in dotted lines with open symbols, or Standard Care (basal/bolus), shown with solid lines and filled symbols, control types were tested. The GRID was executed on the data with sampling periods varying from 1 to 30 min. (A) Mean rise in glucose from meal commencement to time of detection; (B) mean time from meal commencement to time of detection; and (C) percent of meals detected within 2 h from the start of the meal.
- Figure 5 Time in range results of an 18 h in silico study of 10 adult subjects using the UVA/Padova simulator with, from top to bottom, 50g (1), 75g (2), or lOOg (3) CHO meal at 4.5 h.
- Scenarios (A-F) correspond to (A-F) in Figure 5 and Table 2 in no fill, black fill, 45 degree cross hatches, 45 degree lines (from bottom left to top right), -45 degree lines (from top left to bottom right), and horizontal lines, respectively. Means are shown in black crosses, and medians in dots with white borders. Protocols that have statistically significantly different results from the unannounced (B) protocol (paired t-test, p ⁇ 0.05 and p ⁇ 0.01) are shown above the boxes with asterisks, *, and circled asterisks, ⁇ , respectively.
- FIG. 6 Time in range results of a 24 h in silico study of 10 adult subjects using the UVA/Padova simulator with 50, 75, and lOOg CHO meals at 7:00, 13:00, and 19:00, respectively.
- Scenarios (A-G) correspond to (A-G) in [088] Table 3 in no fill, black fill, 45 degree cross hatches, 45 degree lines (from bottom left to top right), -45 degree lines (from top left to bottom right), horizontal lines, and vertical lines, respectively. Means are shown in black crosses, and medians in black dots with white borders. Protocols that have statistically significantly different results from the unannounced (B) protocol (paired t-test, p ⁇ 0.05 and p ⁇ 0.01) are shown above the boxes with asterisks, *, and circled asterisks, ⁇ , respectively.
- McCall AL Farhy LS. Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control. Minerva Endocrinol. Jun 2013;38(2): 145-163.
- Lane JE Shivers JP, Zisser H. Continuous glucose monitors: current status and future developments. Curr Opin Endocrinol Diabetes Obes. Apr 2013;20(2): 106-111.
- Table 1 Characteristics of training clinical datasets, validation clinical datasets, and simulation testing set. Zone-MPC with unannounced meals was used during each trial and simulation. Values after the number of males are presented as median (range) except where indicated. All ranges are calculated with CGM data.
- Time of Peak Glucose after Meal 3 min b 115 (60-120) 111 (86-120) mean ⁇ standard deviation, Calculated as peak within 2 h of the start of the meals.
- Table 2 Standard care alert simulation protocols.
- Table 3 Zone-MPC with inferential control simulation protocols.
- Table 4 Characteristics of an in silico study of 10 adult subjects using the UVa/Padova simulator. Scenarios are A-G as described in
- Table 3 Values are presented as median (range). Metrics that are statistically significantly different results from the unannounced (B) protocol (paired t-test, p ⁇ 0.05 and p ⁇ 0.01) are shown after the values with asterisks, *, and circled asterisks, ⁇ , respectively.
- Peak Glucose after Meal 2 mg/dL 189 (161-222) ® 250 (219-423) 247 (216 ⁇ 21) 235 (204-344) 232 (197-330) 242 (212-361) 242 (212-361)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14862178.2A EP3068290B1 (en) | 2013-11-14 | 2014-10-29 | Glucose rate increase detector: a meal detection module for the health monitoring system |
AU2014349078A AU2014349078B2 (en) | 2013-11-14 | 2014-10-29 | Glucose rate increase detector: a meal detection module for the health monitoring system |
JP2016530936A JP6643558B2 (en) | 2013-11-14 | 2014-10-29 | Glucose rate increase detector and artificial pancreas including same, health monitoring system for real-time prediction of imminent adverse events, and meal detection module for health monitoring system |
CN201480073009.3A CN105899127B (en) | 2013-11-14 | 2014-10-29 | Blood glucose rate rise detection device: the diet detection module for health monitoring systems |
CA2929950A CA2929950C (en) | 2013-11-14 | 2014-10-29 | Glucose rate increase detector: a meal detection module for the health monitoring system |
US15/149,129 US10327681B2 (en) | 2013-11-14 | 2016-05-07 | Glucose rate increase detector: a meal detection module for the health monitoring system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361903965P | 2013-11-14 | 2013-11-14 | |
US61/903,965 | 2013-11-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/149,129 Continuation US10327681B2 (en) | 2013-11-14 | 2016-05-07 | Glucose rate increase detector: a meal detection module for the health monitoring system |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015073211A1 true WO2015073211A1 (en) | 2015-05-21 |
Family
ID=53057869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/062991 WO2015073211A1 (en) | 2013-11-14 | 2014-10-29 | Glucose rate increase detector: a meal detection module for the health monitoring system |
Country Status (7)
Country | Link |
---|---|
US (1) | US10327681B2 (en) |
EP (1) | EP3068290B1 (en) |
JP (1) | JP6643558B2 (en) |
CN (1) | CN105899127B (en) |
AU (1) | AU2014349078B2 (en) |
CA (1) | CA2929950C (en) |
WO (1) | WO2015073211A1 (en) |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10297350B2 (en) | 2016-06-01 | 2019-05-21 | Roche Diabetes Care, Inc. | Risk-based control-to-range |
US10311976B2 (en) | 2016-04-28 | 2019-06-04 | Roche Diabetes Care, Inc. | Bolus calculator with probabilistic carbohydrate measurements |
US10332633B2 (en) | 2016-06-01 | 2019-06-25 | Roche Diabetes Care, Inc. | Control-to-range aggressiveness |
US10332632B2 (en) | 2016-06-01 | 2019-06-25 | Roche Diabetes Care, Inc. | Control-to-range failsafes |
US10327681B2 (en) * | 2013-11-14 | 2019-06-25 | The Regents Of The University Of California | Glucose rate increase detector: a meal detection module for the health monitoring system |
JP2019523482A (en) * | 2016-06-30 | 2019-08-22 | ノボ・ノルデイスク・エー/エス | Plan adherence measurement for insulin treatment based on glucose measurements and insulin pen data |
US10518031B2 (en) | 2016-03-04 | 2019-12-31 | Roche Diabetes Care, Inc. | Bolus calculator with probabilistic glucose measurements |
US10575790B2 (en) | 2016-03-02 | 2020-03-03 | Roche Diabetes Care, Inc. | Patient diabetes monitoring system with clustering of unsupervised daily CGM profiles (or insulin profiles) and method thereof |
US10617363B2 (en) | 2015-04-02 | 2020-04-14 | Roche Diabetes Care, Inc. | Methods and systems for analyzing glucose data measured from a person having diabetes |
US10765807B2 (en) | 2016-09-23 | 2020-09-08 | Insulet Corporation | Fluid delivery device with sensor |
US10777319B2 (en) | 2014-01-30 | 2020-09-15 | Insulet Netherlands B.V. | Therapeutic product delivery system and method of pairing |
US20220061706A1 (en) * | 2020-08-26 | 2022-03-03 | Insulet Corporation | Techniques for image-based monitoring of blood glucose status |
US11324889B2 (en) | 2020-02-14 | 2022-05-10 | Insulet Corporation | Compensation for missing readings from a glucose monitor in an automated insulin delivery system |
US11439754B1 (en) | 2021-12-01 | 2022-09-13 | Insulet Corporation | Optimizing embedded formulations for drug delivery |
US11484652B2 (en) | 2017-08-02 | 2022-11-01 | Diabeloop | Closed-loop blood glucose control systems and methods |
US11547800B2 (en) | 2020-02-12 | 2023-01-10 | Insulet Corporation | User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system |
US11551802B2 (en) | 2020-02-11 | 2023-01-10 | Insulet Corporation | Early meal detection and calorie intake detection |
US11565039B2 (en) | 2018-10-11 | 2023-01-31 | Insulet Corporation | Event detection for drug delivery system |
US11565043B2 (en) | 2018-05-04 | 2023-01-31 | Insulet Corporation | Safety constraints for a control algorithm based drug delivery system |
US11596740B2 (en) | 2015-02-18 | 2023-03-07 | Insulet Corporation | Fluid delivery and infusion devices, and methods of use thereof |
US11607493B2 (en) | 2020-04-06 | 2023-03-21 | Insulet Corporation | Initial total daily insulin setting for user onboarding |
US11628251B2 (en) | 2018-09-28 | 2023-04-18 | Insulet Corporation | Activity mode for artificial pancreas system |
US11684716B2 (en) | 2020-07-31 | 2023-06-27 | Insulet Corporation | Techniques to reduce risk of occlusions in drug delivery systems |
US11738144B2 (en) | 2021-09-27 | 2023-08-29 | Insulet Corporation | Techniques enabling adaptation of parameters in aid systems by user input |
US11801344B2 (en) | 2019-09-13 | 2023-10-31 | Insulet Corporation | Blood glucose rate of change modulation of meal and correction insulin bolus quantity |
US11833329B2 (en) | 2019-12-20 | 2023-12-05 | Insulet Corporation | Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns |
US11857763B2 (en) | 2016-01-14 | 2024-01-02 | Insulet Corporation | Adjusting insulin delivery rates |
US11865299B2 (en) | 2008-08-20 | 2024-01-09 | Insulet Corporation | Infusion pump systems and methods |
US11904140B2 (en) | 2021-03-10 | 2024-02-20 | Insulet Corporation | Adaptable asymmetric medicament cost component in a control system for medicament delivery |
US11929158B2 (en) | 2016-01-13 | 2024-03-12 | Insulet Corporation | User interface for diabetes management system |
US11935637B2 (en) | 2019-09-27 | 2024-03-19 | Insulet Corporation | Onboarding and total daily insulin adaptivity |
USD1020794S1 (en) | 2018-04-02 | 2024-04-02 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
US11957875B2 (en) | 2019-12-06 | 2024-04-16 | Insulet Corporation | Techniques and devices providing adaptivity and personalization in diabetes treatment |
USD1024090S1 (en) | 2019-01-09 | 2024-04-23 | Bigfoot Biomedical, Inc. | Display screen or portion thereof with graphical user interface associated with insulin delivery |
US11969579B2 (en) | 2017-01-13 | 2024-04-30 | Insulet Corporation | Insulin delivery methods, systems and devices |
US11986630B2 (en) | 2020-02-12 | 2024-05-21 | Insulet Corporation | Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk |
US12036389B2 (en) | 2020-01-06 | 2024-07-16 | Insulet Corporation | Prediction of meal and/or exercise events based on persistent residuals |
US12042630B2 (en) | 2017-01-13 | 2024-07-23 | Insulet Corporation | System and method for adjusting insulin delivery |
US12064591B2 (en) | 2013-07-19 | 2024-08-20 | Insulet Corporation | Infusion pump system and method |
US12076160B2 (en) | 2016-12-12 | 2024-09-03 | Insulet Corporation | Alarms and alerts for medication delivery devices and systems |
US12097355B2 (en) | 2023-01-06 | 2024-09-24 | Insulet Corporation | Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation |
US12106837B2 (en) | 2016-01-14 | 2024-10-01 | Insulet Corporation | Occlusion resolution in medication delivery devices, systems, and methods |
US12115351B2 (en) | 2021-09-30 | 2024-10-15 | Insulet Corporation | Secure wireless communications between a glucose monitor and other devices |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10441717B2 (en) | 2014-04-15 | 2019-10-15 | Insulet Corporation | Monitoring a physiological parameter associated with tissue of a host to confirm delivery of medication |
EP3300656A1 (en) | 2016-09-30 | 2018-04-04 | Roche Diabetes Care GmbH | Method and system for determining a carbohydrate intake event from glucose monitoring data indicative of a glucose level, and a non-transitory computer readable medium |
US11311668B2 (en) * | 2016-12-15 | 2022-04-26 | Verily Life Sciences Llc | Auto-calibration of physiological response estimates for closed-loop insulin delivery using patient-selected standardized meals |
CN110392547A (en) * | 2017-03-08 | 2019-10-29 | 雅培糖尿病护理公司 | The systems, devices and methods of health and nutritional surveillance and management are carried out using analysis data |
EP3618713B1 (en) | 2017-05-05 | 2021-12-15 | Eli Lilly and Company | Closed loop control of physiological glucose |
EP3729446A1 (en) | 2017-12-21 | 2020-10-28 | Eli Lilly and Company | Closed loop control of physiological glucose |
CN112313754A (en) | 2018-06-22 | 2021-02-02 | 伊莱利利公司 | Insulin and pramlintide delivery systems, methods and devices |
US11241532B2 (en) | 2018-08-29 | 2022-02-08 | Insulet Corporation | Drug delivery system with sensor having optimized communication and infusion site |
US20220246266A1 (en) * | 2019-06-10 | 2022-08-04 | Bigfoot Biomedical, Inc. | Missed-bolus dose detection and related systems, methods and devices |
CA3146060A1 (en) * | 2019-07-09 | 2021-01-14 | Eli Lilly And Company | Method and system for determining glucose change in a subject |
IL278675B2 (en) * | 2020-11-12 | 2024-04-01 | Dreamed Diabetes Ltd | Method and system for automatic monitoring of diabetes related treatments based on insulin injections |
EP4284468A1 (en) * | 2021-01-28 | 2023-12-06 | Tandem Diabetes Care, Inc. | Systems and methods for automated insulin delivery for diabetes therapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120123234A1 (en) * | 2009-02-26 | 2012-05-17 | Eran Atlas | Method and system for automatic monitoring of diabetes related treatments |
WO2012178134A2 (en) * | 2011-06-23 | 2012-12-27 | University Of Virginia Patent Foundation | Unified platform for monitoring and control of blood glucose levels in diabetic patients |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7806886B2 (en) * | 1999-06-03 | 2010-10-05 | Medtronic Minimed, Inc. | Apparatus and method for controlling insulin infusion with state variable feedback |
WO2004061420A2 (en) * | 2002-12-31 | 2004-07-22 | Therasense, Inc. | Continuous glucose monitoring system and methods of use |
US20080314395A1 (en) * | 2005-08-31 | 2008-12-25 | Theuniversity Of Virginia Patent Foundation | Accuracy of Continuous Glucose Sensors |
EP2051620B1 (en) * | 2006-08-08 | 2010-04-28 | Koninklijke Philips Electronics N.V. | Method and device for monitoring a physiological parameter |
EP2096996A2 (en) * | 2006-11-14 | 2009-09-09 | Novo Nordisk A/S | Adaptive hypoglycaemia alert system and method |
JP2010535057A (en) * | 2007-08-01 | 2010-11-18 | メディンゴ・リミテッド | Portable infusion device with means for monitoring and controlling fluid delivery |
JP5026597B2 (en) * | 2008-11-04 | 2012-09-12 | パナソニック株式会社 | Measuring apparatus, measuring method and program |
US8974439B2 (en) * | 2009-01-02 | 2015-03-10 | Asante Solutions, Inc. | Infusion pump system and methods |
US9919105B2 (en) * | 2009-09-18 | 2018-03-20 | Roche Diagnostics Operations, Inc. | Devices, systems and methods for quantifying bolus doses according to user parameters |
US9171343B1 (en) * | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
CN103263257B (en) * | 2013-05-15 | 2015-07-15 | 深圳市美的连医疗电子股份有限公司 | Remote vital sign measuring system |
AU2014349078B2 (en) * | 2013-11-14 | 2019-07-25 | Regents Of The University Of California | Glucose rate increase detector: a meal detection module for the health monitoring system |
-
2014
- 2014-10-29 AU AU2014349078A patent/AU2014349078B2/en active Active
- 2014-10-29 JP JP2016530936A patent/JP6643558B2/en active Active
- 2014-10-29 CN CN201480073009.3A patent/CN105899127B/en active Active
- 2014-10-29 CA CA2929950A patent/CA2929950C/en active Active
- 2014-10-29 WO PCT/US2014/062991 patent/WO2015073211A1/en active Application Filing
- 2014-10-29 EP EP14862178.2A patent/EP3068290B1/en active Active
-
2016
- 2016-05-07 US US15/149,129 patent/US10327681B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120123234A1 (en) * | 2009-02-26 | 2012-05-17 | Eran Atlas | Method and system for automatic monitoring of diabetes related treatments |
WO2012178134A2 (en) * | 2011-06-23 | 2012-12-27 | University Of Virginia Patent Foundation | Unified platform for monitoring and control of blood glucose levels in diabetic patients |
Non-Patent Citations (39)
Title |
---|
"The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus", N ENGL J MED., vol. 329, 1993, pages 977 - 986 |
BEQUETTE BW: "Challenges and Recent Progress in the Development of a Closed-loop Artificial Pancreas", ANNU REV CONTROL. DEC, vol. 36, no. 2, 2012, pages 255 - 266 |
BRAZEAU ASMIRCESCU HDESJARDINS KLEROUX CSTRYCHAR IEKOE JM: "Rabasa-Lhoret R. Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes", DIABETES RES CLIN PRACT., vol. 99, no. 1, January 2013 (2013-01-01), pages 19 - 23 |
BRETON MFARRET ABRUTTOMESSO DANDERSON SMAGNI LPATEK SDALLA MAN CPLACE JDEMARTINI SDEL FAVERO S: "on behalf of The International Artificial Pancreas Study G. Fully Integrated Artificial Pancreas in Type 1 Diabetes: Modular Closed-Loop Glucose Control Maintains Near Normoglycemia", DIABETES, vol. 61, no. 9, September 2012 (2012-09-01), pages 2230 - 2237 |
BRUTTOMESSO DFARRET ACOSTA SMARESCOTTI MCVETTORE MAVOGARO ATIENGO ADALLA MAN CPLACE JFACCHINETTI A: "Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery and a Model Predictive Control Algorithm: Preliminary Studies in Padova and Montpellier", J DIABETES SCI TECHNOL., vol. 3, no. 5, 2009, pages 1014 - 1021 |
CAMERON FNIEMEYER GBUCKINGHAM BA: "Probabilistic Evolving Meal Detection and Estimation of Meal Total Glucose Appearance", J DIABETES SCI TECHNOL., vol. 3, no. 5, 2009, pages 1022 - 1030, XP055311666, DOI: 10.1177/193229680900300505 |
COBELLI CRENARD EKOVATCHEV BPKEITH-HYNES PBEN BRAHIM NPLACE JDEL FAVERO SBRETON MFARRET ABRUTTOMESSO D: "Pilot studies of wearable outpatient artificial pancreas in type 1 diabetes", DIABETES CARE, vol. 35, no. 9, September 2012 (2012-09-01), pages e65 - 67 |
DASSAU EBEQUETTE BWBUCKINGHAM BADOYLE III FJ: "Detection of a Meal Using Continuous Glucose Monitoring (CGM): Implications for an Artificial 0-cell", DIABETES CARE, vol. 31, no. 2, 2008, pages 295 - 300, XP002601932, DOI: 10.2337/dc07-1293 |
DASSAU EHERRERO PZISSER HBUCKINGHAM BAJOVANOVIC LDALLA MAN CCOBELLI CVEHI JDOYLE III FJ: "Implications of Meal Library & Meal Detection to Glycemic Control of Type 1 Diabetes Mellitus through MPC Control", PROC 17TH IFAC WORLD CONGRESS, 2008, pages 4228 - 4233 |
DASSAU ELEE JJRENARD EZISSER HDOYLE III FJ: "Clinical and Engineering Aspects of IP Insulin Delivery in Closed Loop Study - The Diaport Experience", PAPER PRESENTED AT: 6TH INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES AND TREATMENTS FOR DIABETES, 2013 |
DASSAU EZISSER HHARVEY RAPERCIVAL MWGROSMAN BBEVIER WATLAS EMILLER SNIMRI RJOVANOVIC L: "Clinical Evaluation of a Personalized Artificial Pancreas", DIABETES CARE, vol. 36, no. 4, 2013, pages 801 - 809 |
DASSAU EZISSER HPALERM CCBUCKINGHAM BAJOVANOVIC LDOYLE III FJ: "Modular Artificial Ø-Cell System: A Prototype for Clinical Research", J DIABETES SCI TECHNOL., vol. 2, no. 5, 2008, pages 863 - 872 |
DUNN TCEASTMAN RCTAMADA JA: "Rates of Glucose Change Measured by Blood Glucose Meter and the GlucoWatch Biographer During Day, Night, and Around Mealtimes", DIABETES CARE, vol. 27, no. 9, September 2004 (2004-09-01), pages 2161 - 2165, XP055480689, DOI: 10.2337/diacare.27.9.2161 |
ELLERI DALLEN JMBIAGIONI MKUMARESWARAN KLEELARATHNA LCALDWELL KNODALE MWILINSKA MEACERINI CLDUNGER DB: "Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes", PEDIATR DIABETES, vol. 13, no. 6, September 2012 (2012-09-01), pages 449 - 453 |
GONDHALEKAR RDASSAU EZISSER HDOYLE III FJ: "Periodic-Zone Model Predictive Control for Diurnal Closed-loop Operation of an Artificial Pancreas", DIABETES SCIENCE AND TECHNOLOGY, 2013 |
GROSMAN BDASSAU EZISSER HCJOVANOVIC LDOYLE III FJ: "Zone model predictive control: a strategy to minimize hyper- and hypoglycemic events", J DIABETES SCI TECHNOL., vol. 4, no. 4, July 2010 (2010-07-01), pages 961 - 975, XP055102711 |
HARVEY RADASSAU EBEVIER WSEBORG DEJOVANOVIC LDOYLE III FJZISSER H: "Clinical Evaluation of an Automated Artificial Pancreas Using Zone-Model Predictive Control and Health Monitoring System", DIABETES TECHNOL. & THER., 2013 |
HARVEY RADASSAU EZISSER HSEBORG DEJOVANOVIC LDOYLE III FJ: "Clinical Evaluation of the Health Monitoring System (HMS", PAPER PRESENTED AT: 6TH INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES AND TREATMENTS FOR DIABETES, 2013 |
HARVEY RADASSAU EZISSER HSEBORG DEJOVANOVIC LDOYLE III FJ: "Design of the Health Monitoring System for the Artificial Pancreas: Low Glucose Prediction Module", J DIABETES SCI TECHNOL., November 2012 (2012-11-01) |
HARVEY, RA ET AL.: "Design of the Health Monitoring System for the Artificial Pancreas: Low Glucose Prediction Module", JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, vol. 6, no. 6, 1 November 2012 (2012-11-01), pages 1345 - 1354, XP055286426, DOI: 10.1177/193229681200600613 * |
HOVORKA RKUMARESWARAN KHARRIS JALLEN JMELLERI DXING DYKOLLMAN CNODALE MMURPHY HRDUNGER DB: "Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies", BRIT MED J., April 2011 (2011-04-01), pages 342 |
LANE JESHIVERS JPZISSER H: "Continuous glucose monitors: current status and future developments", CURR OPIN ENDOCRINOL DIABETES OBES., vol. 20, no. 2, April 2013 (2013-04-01), pages 106 - 111 |
LEE HBUCKINGHAM BAWILSON DMBEQUETTE BW: "A Closed-Loop Artificial Pancreas Using Model Predictive Control and a Sliding Meal Size Estimator", J DIABETES SCI TECHNOL., vol. 3, no. 5, 2009, pages 1082 - 1090, XP002646296 |
LEE JJDASSAU EZISSER HJOVANOVIC LDOYLE III FJ: "Evaluation of Zone-MPC for Intraperitoneal Insulin Delivery", PAPER PRESENTED AT: AMERICAN DIABETES ASSOCIATION 72ND SCIENTIFIC SESSIONS, 2012 |
LEE JJZISSER HCDASSAU EFARRET APLACE JPELLETIER MJHARVEY RADOYLE III FJRENARD E, CLINICAL RESULTS OF ARTIFICIAL PANCREAS USING INTRAPERITONEAL INSULIN DELIVERY PAPER PRESENTED AT: AMERICAN DIABETES ASSOCIATION 73ND SCIENTIFIC SESSIONS, 2013 |
MCCALL ALFARHY LS: "Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control", MINERVA ENDOCRINOL., vol. 38, no. 2, June 2013 (2013-06-01), pages 145 - 163 |
NIMRI RATLAS EAJZENSZTEJN MMILLER SORON TPHILLIP M: "Feasibility study of automated overnight closed-loop glucose control under MD-logic artificial pancreas in patients with type 1 diabetes: the DREAM Project", DIABETES TECHNOL THER., vol. 14, no. 8, August 2012 (2012-08-01), pages 728 - 735 |
OLINDER ALNYHLIN KTSMIDE B: "Reasons for missed meal-time insulin boluses from the perspective of adolescents using insulin pumps: 'lost focus", PEDIATR DIABETES, vol. 12, no. 4, June 2011 (2011-06-01), pages 402 - 409 |
PALERM CCWILLIS JPDESEMONE JBEQUETTE BW: "Hypoglycemia prediction and detection using optimal estimation", DIABETES TECHNOL THER., vol. 7, no. 1, February 2005 (2005-02-01), pages 3 - 14 |
RAHAGHI FNGOUGH DA: "Blood glucose dynamics", DIABETES TECHNOL THER., vol. 10, no. 2, April 2008 (2008-04-01), pages 81 - 94 |
RENARD EPLACE JCANTWELL MCHEVASSUS HPALERM CC: "Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas", DIABETES CARE, vol. 33, no. 1, January 2010 (2010-01-01), pages 121 - 127 |
SEBORG DEEDGAR TFMELLICHAMP DADOYLE III FJ: "Process Dynamics and Control.", 2011, JOHN WILEY & SONS |
See also references of EP3068290A4 |
SHEPARD JAGONDER-FREDERICK LVAJDA KKOVATCHEV B.: "Patient perspectives on personalized glucose advisory systems for type 1 diabetes management", DIABETES TECHNOL THER., vol. 14, no. 10, October 2012 (2012-10-01), pages 858 - 861 |
STEIL GMPALERM CCKURTZ NVOSKANYAN GROY APAZ SKANDEEL FR: "The effect of insulin feedback on closed loop glucose control", J CLIN ENDOCRINOL METAB., vol. 96, no. 5, May 2011 (2011-05-01), pages 1402 - 1408, XP055086381, DOI: 10.1210/jc.2010-2578 |
VAN BON ACKOHINOR MJHOEKSTRA JBVON BASUM GDEVRIES JH: "Patients' perception and future acceptance of an artificial pancreas", J DIABETES SCI TECHNOL., vol. 4, no. 3, May 2010 (2010-05-01), pages 596 - 602 |
VAN HEUSDEN KDASSAU EZISSER HCSEBORG DEDOYLE III FJ: "Control-relevant models for glucose control using a priori patient characteristics", IEEE TRANS BIOMED ENG., vol. 59, no. 7, July 2012 (2012-07-01), pages 1839 - 1849, XP011490114, DOI: 10.1109/TBME.2011.2176939 |
WEINZIMER SASHERR JLCENGIZ EKIM GRUIZ JLCARRIA LVOSKANYAN GROY ATAMBORLANE WV: "Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes", DIABETES CARE, vol. 35, no. 10, October 2012 (2012-10-01), pages 1994 - 1999 |
ZISSER HCDASSAU EBEVIER WHARVEY RAJOVANOVIC LDOYLE III FJ: "Clinical Evaluation of a Fully-Automated Artificial Pancreas using Zone-Model Predictive Control with Health Monitoring System", PAPER PRESENTED AT: AMERICAN DIABETES ASSOCIATION 72ND SCIENTIFIC SESSIONS, 2012 |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11865299B2 (en) | 2008-08-20 | 2024-01-09 | Insulet Corporation | Infusion pump systems and methods |
US12064591B2 (en) | 2013-07-19 | 2024-08-20 | Insulet Corporation | Infusion pump system and method |
US10327681B2 (en) * | 2013-11-14 | 2019-06-25 | The Regents Of The University Of California | Glucose rate increase detector: a meal detection module for the health monitoring system |
US10777319B2 (en) | 2014-01-30 | 2020-09-15 | Insulet Netherlands B.V. | Therapeutic product delivery system and method of pairing |
US11386996B2 (en) | 2014-01-30 | 2022-07-12 | Insulet Netherlands B.V. | Therapeutic product delivery system and method of pairing |
US11596740B2 (en) | 2015-02-18 | 2023-03-07 | Insulet Corporation | Fluid delivery and infusion devices, and methods of use thereof |
US10617363B2 (en) | 2015-04-02 | 2020-04-14 | Roche Diabetes Care, Inc. | Methods and systems for analyzing glucose data measured from a person having diabetes |
US11929158B2 (en) | 2016-01-13 | 2024-03-12 | Insulet Corporation | User interface for diabetes management system |
US11857763B2 (en) | 2016-01-14 | 2024-01-02 | Insulet Corporation | Adjusting insulin delivery rates |
US12106837B2 (en) | 2016-01-14 | 2024-10-01 | Insulet Corporation | Occlusion resolution in medication delivery devices, systems, and methods |
US10575790B2 (en) | 2016-03-02 | 2020-03-03 | Roche Diabetes Care, Inc. | Patient diabetes monitoring system with clustering of unsupervised daily CGM profiles (or insulin profiles) and method thereof |
US10518031B2 (en) | 2016-03-04 | 2019-12-31 | Roche Diabetes Care, Inc. | Bolus calculator with probabilistic glucose measurements |
US10311976B2 (en) | 2016-04-28 | 2019-06-04 | Roche Diabetes Care, Inc. | Bolus calculator with probabilistic carbohydrate measurements |
US10332633B2 (en) | 2016-06-01 | 2019-06-25 | Roche Diabetes Care, Inc. | Control-to-range aggressiveness |
US10297350B2 (en) | 2016-06-01 | 2019-05-21 | Roche Diabetes Care, Inc. | Risk-based control-to-range |
US10332632B2 (en) | 2016-06-01 | 2019-06-25 | Roche Diabetes Care, Inc. | Control-to-range failsafes |
US11605461B2 (en) | 2016-06-01 | 2023-03-14 | Roche Diabetes Care, Inc. | Risk-based control-to-range blood glucose diabetes management device |
US11464447B2 (en) | 2016-06-30 | 2022-10-11 | Novo Nordisk A/S | Regimen adherence measure for insulin treatment based on glucose measurements and insulin pen data |
JP2019523482A (en) * | 2016-06-30 | 2019-08-22 | ノボ・ノルデイスク・エー/エス | Plan adherence measurement for insulin treatment based on glucose measurements and insulin pen data |
US10765807B2 (en) | 2016-09-23 | 2020-09-08 | Insulet Corporation | Fluid delivery device with sensor |
US12076160B2 (en) | 2016-12-12 | 2024-09-03 | Insulet Corporation | Alarms and alerts for medication delivery devices and systems |
US11969579B2 (en) | 2017-01-13 | 2024-04-30 | Insulet Corporation | Insulin delivery methods, systems and devices |
US12042630B2 (en) | 2017-01-13 | 2024-07-23 | Insulet Corporation | System and method for adjusting insulin delivery |
US11484652B2 (en) | 2017-08-02 | 2022-11-01 | Diabeloop | Closed-loop blood glucose control systems and methods |
USD1020794S1 (en) | 2018-04-02 | 2024-04-02 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
US11565043B2 (en) | 2018-05-04 | 2023-01-31 | Insulet Corporation | Safety constraints for a control algorithm based drug delivery system |
US12090301B2 (en) | 2018-05-04 | 2024-09-17 | Insulet Corporation | Safety constraints for a control algorithm based drug delivery system |
US11628251B2 (en) | 2018-09-28 | 2023-04-18 | Insulet Corporation | Activity mode for artificial pancreas system |
US11565039B2 (en) | 2018-10-11 | 2023-01-31 | Insulet Corporation | Event detection for drug delivery system |
USD1024090S1 (en) | 2019-01-09 | 2024-04-23 | Bigfoot Biomedical, Inc. | Display screen or portion thereof with graphical user interface associated with insulin delivery |
US11801344B2 (en) | 2019-09-13 | 2023-10-31 | Insulet Corporation | Blood glucose rate of change modulation of meal and correction insulin bolus quantity |
US11935637B2 (en) | 2019-09-27 | 2024-03-19 | Insulet Corporation | Onboarding and total daily insulin adaptivity |
US11957875B2 (en) | 2019-12-06 | 2024-04-16 | Insulet Corporation | Techniques and devices providing adaptivity and personalization in diabetes treatment |
US11833329B2 (en) | 2019-12-20 | 2023-12-05 | Insulet Corporation | Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns |
US12036389B2 (en) | 2020-01-06 | 2024-07-16 | Insulet Corporation | Prediction of meal and/or exercise events based on persistent residuals |
US11551802B2 (en) | 2020-02-11 | 2023-01-10 | Insulet Corporation | Early meal detection and calorie intake detection |
US11986630B2 (en) | 2020-02-12 | 2024-05-21 | Insulet Corporation | Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk |
US11547800B2 (en) | 2020-02-12 | 2023-01-10 | Insulet Corporation | User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system |
US11324889B2 (en) | 2020-02-14 | 2022-05-10 | Insulet Corporation | Compensation for missing readings from a glucose monitor in an automated insulin delivery system |
US11607493B2 (en) | 2020-04-06 | 2023-03-21 | Insulet Corporation | Initial total daily insulin setting for user onboarding |
US11684716B2 (en) | 2020-07-31 | 2023-06-27 | Insulet Corporation | Techniques to reduce risk of occlusions in drug delivery systems |
US20220061706A1 (en) * | 2020-08-26 | 2022-03-03 | Insulet Corporation | Techniques for image-based monitoring of blood glucose status |
US11904140B2 (en) | 2021-03-10 | 2024-02-20 | Insulet Corporation | Adaptable asymmetric medicament cost component in a control system for medicament delivery |
US11738144B2 (en) | 2021-09-27 | 2023-08-29 | Insulet Corporation | Techniques enabling adaptation of parameters in aid systems by user input |
US12115351B2 (en) | 2021-09-30 | 2024-10-15 | Insulet Corporation | Secure wireless communications between a glucose monitor and other devices |
US11439754B1 (en) | 2021-12-01 | 2022-09-13 | Insulet Corporation | Optimizing embedded formulations for drug delivery |
US12097355B2 (en) | 2023-01-06 | 2024-09-24 | Insulet Corporation | Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation |
Also Published As
Publication number | Publication date |
---|---|
AU2014349078A1 (en) | 2016-06-02 |
US20160256087A1 (en) | 2016-09-08 |
CA2929950A1 (en) | 2015-05-21 |
JP2017501765A (en) | 2017-01-19 |
CN105899127B (en) | 2019-09-24 |
AU2014349078B2 (en) | 2019-07-25 |
JP6643558B2 (en) | 2020-02-12 |
EP3068290B1 (en) | 2020-08-26 |
EP3068290A1 (en) | 2016-09-21 |
CN105899127A (en) | 2016-08-24 |
CA2929950C (en) | 2019-01-15 |
US10327681B2 (en) | 2019-06-25 |
EP3068290A4 (en) | 2016-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2929950C (en) | Glucose rate increase detector: a meal detection module for the health monitoring system | |
JP7457072B2 (en) | Closed-loop control of physiological glucose | |
US20220118180A1 (en) | Usability Features for Integrated Insulin Delivery System | |
EP2986215B1 (en) | Discretionary insulin delivery systems and methods | |
Harvey et al. | Design of the glucose rate increase detector: a meal detection module for the health monitoring system | |
EP2475356B1 (en) | Devices, systems and methods for adjusting fluid delivery parameters | |
US20170135643A1 (en) | Methods for reducing false hypoglycemia alarm occurrence | |
TW201837762A (en) | Insulin-on-board accounting in an artificial pancreas system | |
US20200015760A1 (en) | Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems | |
JP2012519018A (en) | Method and system for automatically monitoring diabetes related therapy | |
CN116670774A (en) | Closed-loop control method and system for improving blood glucose response after non-notification source blood glucose fluctuation | |
JP7463491B2 (en) | Method and system for determining glucose change in a subject - Patents.com | |
JP2023526663A (en) | Insulin delivery system, method and device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14862178 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2929950 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2014862178 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014862178 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016530936 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014349078 Country of ref document: AU Date of ref document: 20141029 Kind code of ref document: A |